Wuxi Bio (02269) and Doxis Biopharma have reached a research service cooperation agreement with Aadi Bioscience (AADI.US) on three innovative ADCs.

The world's leading Contract Research, Development, and Manufacturing (CRDMO) services company, WUXI BIO (02269), announced today a research service cooperation agreement with Hangzhou DAC Biotechnology Co., Ltd (DAC) and Aadi Bioscience (AADI.US) to empower Aadi in the development of three next-generation Antibody-Drug Conjugates (ADCs) in preclinical stage. This collaboration combines the technical strengths of WUXI BIO and DAC, utilizing WUXI BIO's innovative antibody discovery technology platform and DAC's advanced payload and linker platform technology. As per the agreement terms, Aadi will make an upfront payment of $44 million to WUXI BIO and DAC, with potential development milestone payments totaling up to $265 million and commercial milestone payments of $540 million, as well as single-digit royalties on sales. Dr. Chris Chen, CEO of WUXI BIO, stated, "We are pleased to accelerate the development of precise therapies for the most challenging cancers for Aadi through advanced antibody discovery services. This collaboration highlights WUXI BIO's recognized leadership in biologics discovery services and further validates our strength in providing a comprehensive discovery technology platform for global partners in the next-generation biologics field. We look forward to working with Aadi and DAC to expedite the development and commercialization of these products for the benefit of patients worldwide." Dr. David Lennon, President and CEO of Aadi Bioscience, remarked, "We are excited to collaborate with WUXI BIO and DAC to advance the development of these innovative products. With the concept validation of first-generation ADCs, we have carefully selected targets widely expressed in tumors and expect these next-generation ADC products to provide superior therapy for cancer patients." Dr. Yongxin Zhao, Founder and CEO of DAC, expressed, "We are honored to establish this strategic partnership with Aadi and WUXI BIO, as Aadi's deep understanding and commercialization capabilities in precision oncology will provide strong support for the continued development of these innovative ADC projects. In the future, DAC will continue to expand strategic cooperation with WUXI BIO to empower more innovative ADC candidates."